Immunosuppressant Management in Renal Transplant Patients with COVID-19.
Biomed Res Int
; 2021: 9318725, 2021.
Article
in English
| MEDLINE | ID: covidwho-1476889
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic poses a special risk for both immunosuppressed patients, especially transplant recipients. Although the knowledge about this infection is growing, many uncertainties remain, particularly regarding the kidney. Kidney transplant recipients (KDRs) should be considered immunocompromised hosts since a potential risk for infection, comorbidity, and immunosuppression exposure exists. Additionally, the management of immunosuppressive agents in KDRs remains challenging. Potential drug interactions with immunosuppressive treatment escalated the risk of unwanted side effects. In this review, we aimed to attain an augmented awareness and improved management immunosuppressant for COVID-19 KDRs.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Kidney Transplantation
/
COVID-19
/
Immunosuppressive Agents
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Biomed Res Int
Year:
2021
Document Type:
Article
Affiliation country:
2021
Similar
MEDLINE
...
LILACS
LIS